Post on 04-Oct-2020
transcript
Sysmex Journal International Vol. 25 No. 1 (2015)
− 1 −
INTRODUCTIONIn recent years, healthcare infrastructures have beensteadily constructed in emerging markets. In addition,rapid rates of economic growth have made healthcareinformation more accessible worldwide.Thus, people have become more aware of health andhealthcare, with dramatically increasing demands formedical care and clinical testing. In developed countries,regional needs have diversified, such as medical costsuppression due to the aging society and widely-spreading personalized healthcare.To address the dynamic healthcare terrain, we launchedthe XN-Series in 2011, which improved the efficiencyand clinical values of blood cell count testing. Now weintroduce the XN-L series; compact automatedhematology analyzers that are based on XN seriesfunctionality, operability, and clinical parameters 1-3) (Fig. 1).These analyzers are among the world's smallest and are
equipped with advanced testing modalities includingreticulocyte (RET) measurement functions, a low WBCmode, and body fluid mode. The XN-L also has thefeatures of conventional products including: 8 CBCparameters, 6 WBC classifications, and trace analytemeasurement. This series includes superior service andsupport systems that correspond to the Sysmex NetworkCommunication Systems (SNCS®) 4), contributing to safeand efficient laboratory test environments. One analyzerin this line, the XN-550, features automatedRerun/Repeat/Reflex functions as an added capability.Furthermore, this product line is already equipped toprovide future enhancements, including an optionalapplication to detect the infected erythrocytes in malarialinfection, which is one of the three most prevalentinfections worldwide. Sysmex is committed to advancinghematology technologies in order to further develop theclinical use of the automated blood cell analyzer. In thisreport, XN-L series will be introduced.
OverOverview and Features of the Automated Hematology Analyzerview and Features of the Automated Hematology Analyzer
XN-L Series
Overview and Features of the Automated Hematology Analyzer
XN-L Series
Introduction of Products
Yoshikoshiko Ho HAMAAMAGUCHIGUCHI*1*1, , Tamiaki Kamiaki KONDOONDO*1*1, Rie N, Rie NAKAIAKAI*1*1, , Yasuhiro Oasuhiro OCHICHI*1*1, , Tomonoromonori Oi OKAZAKIKAZAKI*2*2,
KinKinya Ua UCHIHASHICHIHASHI*2*2, , Takashi Makashi MORIKAORIKAWA*1*1
*1*1 Scientific Aff Scientific Affairsairs, Sysme, Sysmex Corx Corporporation, 1-3-2 Murotani, Nishi-ku, Kation, 1-3-2 Murotani, Nishi-ku, Kobe 651-2241, Jobe 651-2241, Japanapan*2*2 Hematology Product Engineer Hematology Product Engineering Division, Sysmeing Division, Sysmex Corx Corporporationation
Yoshiko HAMAGUCHI*1, Tamiaki KONDO*1, Rie NAKAI*1, Yasuhiro OCHI*1, Tomonori OKAZAKI*2,
Kinya UCHIHASHI*2, Takashi MORIKAWA*1
*1 Scientific Affairs, Sysmex Corporation, 1-3-2 Murotani, Nishi-ku, Kobe 651-2241, Japan*2 Hematology Product Engineering Division, Sysmex Corporation
Note: This article is translated and republished from Sysmex Journal Web Vol. 16 No. 1 2015.
Sysmex Journal International Vol. 25 No. 1 (2015)
− 2 −
Table 1 Reportable parameters
MAIN SPECIFICATIONS
1. Name
1) Name: Automated Hematology Analyzer XN-L series2) Model: XN-550 (Sampler type)
XN-450 (Cap-piercing type)XN-350 (Open type)
2. Applications
These devices are hematology analyzers for blood testingusing human blood. Blood should be anticoagulated withEDTA-2K, EDTA-3K, and EDTA-2Na for use on theanalyzers. Body fluids, such as cerebrospinal, pleural,peritoneal, and synovial fluids, can also be measured.
3. Reportable parameters
There are 35 reportable whole blood parameters and 7reportable body fluid parameters. For details, see Table1.
4. Main research parameters
Fragmented red blood cell count (FRC#), fragmented red
blood cell ratio (FRC%), high fluorescent lymphocytecount (HFLC#), and high fluorescent lymphocyte ratio(HFLC%).
5. Sample volume
Sample volumes to be aspirated are 25µL and 70µL forwhole blood and diluted blood/body fluid, respectively.For details, see Table 2.
6. Throughput
Throughput is up to approx. 70 samples per hour. Fordetails, see Table 3.
7. Dimensions and weight
Dimensions (width × depth × height) and weights areshown in Table 4.
8. Reagents
Reagents and their measurement channels are shown inTable 5.
CBC
Discrete
* The availability of functions depends on the system configuration.
Analysis Mode
Whole Bloodmode
Body Fluid mode*
Detector/Channel Parameter
DIFF
RET
WDF
RET*
RBC, WDF
WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT
RDW-SD, RDW-CV, PDW, MPV, P-LCR, PCT
NEUT#, LYMPH#, MONO#, EO#, BASO#, NEUT%,
LYMPH%, MONO%, EO%, BASO%, IG#, IG%
RBC-BF, WBC-BF, MN#, PMN#, MN%, PMN%, TC-BF—
RBC/PLT, HGB, WDF
RET#, RET%, IRF, LFR, MFR, HFR, RET-He, IPF#, IPF
Sysmex Journal International Vol. 25 No. 1 (2015)
− 3 −
25µL
25µL
25µL
70µL*1
70µL
70µL
1mL
250µL
1mL
300µL
250µL
100µL
300µL
140µL
1mL
300µL
140µL
XN-550/XN-450
XN-350
*1: Use diluted blood prepared by diluting 20µL of whole blood1:7.*2: The availability of body fluid analysis function depends on the system configuration.
Analysis method
Sampler analysis(XN-550)
Manual analysis
Manual analysis
Specimen
Specimen
Wholeblood
Whole blood
Wholeblood
Dilutedblood
Diluted blood
Bodyfluid*2
Body fluid*
Test tube
Test tube
Regular sample tube
Regular sample tube
RBT micro collection tube
Regular sample tube
RBT micro collection tube
Micro collection tube
Regular sample tube
Regular sample tube
Micro collection tube
Micro collection tube
Cap
Cap
Close
Close
Close
Open
Close
Open
Open
Open
Close
Open
Open
Open
Aspirated sample volume
Aspirated sample volume
Required sample volume
* The availability of body fluid analysis function depends on the system configurations.
Analysis method
Table 2 Sample volume
Table 3 Throughput
*1: The throughput depends on the system configuration.*2: The availability of functions depends on the system configurations.
Analysis mode
Whole blood
Low WBC*2
Pre-Dilution
Body fluid*2 —
Discrete Throughput
Approx. 60 samples/hour (approx. 70 samples/hour*1)
Approx. 35 samples/hour
Approx. 55 samples/hour
Approx. 30 samples/hour
Approx. 60 samples/hour
Approx. 30 samples/hour
Approx. 30 samples/hour
CBC
CBC
CBC+DIFF
CBC+DIFF
CBC+DIFF
CBC+RET*2
CBC+DIFF+RET*2
CBC+DIFF+RET*2
CBC+DIFF+RET*2
TECHNOLOGY
1. Measurement principles
1) Flow cytometryThe XN-L uses reliable flow cytometry technology usinga semiconductor laser which inherits the technology ofXN-Series 4) to provide high-performance measurementsin a compact design. Blood cells are treated with specificreagents, and are expanded on multi-dimensionalscattergrams through the conversion of forward scattered-, side scattered-, and side fluorescent light into electricalimpulses. Each scattergram is analyzed using originaltechnologies to calculate measurements (Table 6). Thelow WBC and body fluid modes improve accuracy byincreasing the amount of blood cells counted. Also,reticulocyte hemoglobin equivalents (RET-He) andimmature platelet fraction (IPF) are determined.
2) Hydro dynamic focusing method (direct current:DC detection method) 5)
Red blood cell and platelet counts are determined usingHydro dynamic focusing method. In principle, thecoincidence and recount of blood cells are minimized,facilitating accurate measurements of blood counts andvolumes.
3) SLS hemoglobin method 6)
Hemoglobin concentrations are determined by the SLShemoglobin method without using toxin or specialoxidizing agents.
In principle, blood cells are lysed with sodium laurylsulfate (SLS), followed by colorimetric measurements.This method is suitable for automation.
2. Body fluid mode 1)
The devices are equipped with a body fluid mode.Without sample pretreatment, white blood cell (WBC-BF) and red blood cell (RBC-BF) counts as well asmononuclear (MN#, MN%) and polymorphonuclear(PMN#, PMN%) leukocyte ratios can be determined andreported. The measurement accuracy is improved byincreasing the particle counts approximately tenfold inwhite blood cells and threefold in red blood cells, whencompared to the whole blood mode.
3. Low WBC mode 2,3)
The devices are equipped with a low WBC mode,facilitating the accurate determination of low WBCcounts. In principle, sample volume to be measured isdoubled, as compared with the whole blood mode,thereby improving the measurement accuracy.
4. Automated dispensing function of diluent
The devices dispense 120µL of CELLPACK DCL into anempty micro collection tube. Subsequently, diluted bloodprepared with 20µL of sample can be measured. Thisfacilitates the measurement of small blood volumeswhich is especially useful for patient populationsincluding geriatric and infant.
Sysmex Journal International Vol. 25 No. 1 (2015)
− 4 −
Table 4 Dimensions and weight
Table 5 Reagents
XN-550
XN-450
XN-350
AnalyzerMonitor
Analyzer
Analyzer
Dimensions (width × depth × height)
Approx. 450 × 660 × 450 mmApprox. 267 × 205 × 240 mm
Approx. 450 × 460 × 440 mm
Approx. 450 × 460 × 510 mm
Weight
Approx. 53 kgApprox. 3 kg
Approx. 35 kg
Approx. 35 kg
*1: Use of CELLPACK DST depends on the system configuration.*2: The availability of functions depends on the system configurations.
Channel
Each channel
HGB channel
WDF channel
RET channel*2
Reagent type
Diluent (concentrated reagent)
Diluent
Hemolytic agent
Hemolytic agent
Stain solution
Diluent
Stain solution
Product name
CELLPACK DST*1
CELLPACK DCL
SULFOLYSER
Lysercell WDF
Fluorocell WDF
CELLPACK DFL
Fluorocell RET
BASIC PERFORMANCE
1. Within-run reproducibility1) Whole blood modeWithin-run reproducibility was demonstrated using threeblood samples from healthy volunteers each with 10-consecutive measurements in whole blood mode. Resultsare shown in Table 7. The CV values of main parameterswere WBC : 1.3 - 2.0%, RBC : 0.3 - 0.7%, HGB : 0.3 -0.5%, HCT : 0.2 - 0.8%, PLT-I : 2.0 - 2.2%, and PLT-O :0.8 - 2.1%.
2) Body fluid modeWithin-run reproducibility in body fluid mode wasdemonstrated by preparing samples in three differentconcentrations using quality control material (XNCHECK BF) and measuring each in 10-consecutive runs.This data is shown in Table 8. The CV values of mainparameters were WBC-BF : 5.6 - 9.3%, RBC-BF : 2.4 -10.6% , and TC-BF# : 5.6 - 9.3%.
2. Correlation1) Whole blood modeA correlation between XN-550 (XN-L series) and XN-1000 (XN-Series) in the whole blood mode using patient blood samples (EDTA-2K added, N = 106, provided by the Improvement for Measurement and Diagnostic Technique Project at Department of Laboratory Tests, University of Tsukuba Hospital, Japan) is shown in Fig. 2. The correlation coefficients (r) of main parameters were WBC : 0.9974, RBC : 0.9984, HGB : 0.9987, HCT : 0.9976, and PLT : 0.9982.
2) Body fluid modeA correlation between XN-550 (XN-L series) and XN-1000 (XN-Series) using 20 celomic fluid, 12 cerebrospinal fluid, and 23 peritoneal dialysate in the body fluid mode is shown in Fig. 3. The correlation coefficients (r) of each parameterwas WBC-BF : 0.9994, RBC-BF : 0.9995, and TC-BF# :0.9993.
3. Minimum detection sensitivity1) Whole blood modeMinimum sensitivities (limit of blank : LoB, limit ofdetection : LoD, and limit of quantitation : LoQ) inmeasuring a quality control material (e-CHECK) forwhich the concentration has been adjusted andCELLPACK DCL in the whole blood mode are shown inTable 9. The minimum detection sensitivities of mainparameters were WBC (CBC + DIFF mode) : 0.01 ×109/L, RBC : 0.00 × 1012/L, and PLT : 1 × 109/L.
2) Low WBC modeMinimum sensitivities (LoB, LoD, and LoQ) inmeasuring a quality control material (e-CHECK) forwhich the concentration has been adjusted andCELLPACK DCL in the low WBC mode are shown inTable 10. The minimum detection sensitivities of mainparameters were WBC : 0.01 × 109/L, RBC : 0.00 ×1012/L, and PLT : 1 × 109/L.
3) Body fluid modeMinimum sensitivities (LoB, LoD, and LoQ) inmeasuring a quality control material (e-CHECK) forwhich the concentration has been adjusted andCELLPACK DCL in the body fluid mode are shown inTable 11. The minimum detection sensitivities of mainparameters were WBC-BF : 0.001 × 109/L, RBC-BF :0.000 × 1012/L, and TC-BF# : 0.001 × 109/L.
Sysmex Journal International Vol. 25 No. 1 (2015)
− 5 −
Table 6 Measurement channels and detection parameters
WDF
RET*
Detection parameters
Forward scattered light - side scattered light (CBC)
Side scattered light - side fluorescence light (CBC + DIFF)
Side fluorescence light - forward scattered light
Channel Detection parameters
White blood cell count
WBC 6 differentiation for white blood cell
Reticulocyte
* The availability of functions depends on your system configurations.
Sysmex Journal International Vol. 25 No. 1 (2015)
− 6 −
Table 7 Within-run reproducibility of the whole blood mode
AVE.
SD
CV
AVE.
SD
CV
AVE.
SD
CV
1
2
3
WBC-C*1
(109/L )
6.948
0.140
2.0%
9.091
0.117
1.3%
3.661
0.046
1.3%
WBC-D*2
(109/L )
6.915
0.138
2.0%
9.012
0.114
1.3%
3.638
0.048
1.3%
RBC(1012/L )
5.206
0.014
0.3%
5.014
0.035
0.7%
4.783
0.030
0.6%
HGB(g/L )
162.7
0.7
0.4%
148.0
0.7
0.5%
154.2
0.4
0.3%
HCT(L/L )
0.5020
0.0012
0.2%
0.4682
0.0035
0.8%
0.4672
0.0030
0.7%
MCV(fL)
96.43
0.07
0.1%
93.38
0.15
0.2%
97.68
0.11
0.1%
MCH(pg)
31.25
0.16
0.5%
29.52
0.23
0.8%
32.25
0.22
0.7%
MCHC(g/L )
324.1
1.9
0.6%
316.0
2.6
0.8%
330.1
2.1
0.6%
PLT-I(109/L )
312.1
6.2
2.0%
259.6
5.6
2.2%
174.5
3.8
2.2%
PLT-O(109/L )
298.2
2.3
0.8%
250.6
4.1
1.6%
170.6
3.7
2.1%
AVE.
SD
CV
AVE.
SD
CV
AVE.
SD
CV
1
2
3
NEUT%(%)
56.59
0.82
1.5%
74.78
0.51
0.7%
44.86
0.69
1.5%
LYMPH%(%)
34.51
0.91
2.6%
14.19
0.52
3.6%
46.58
0.78
1.7%
MONO%(%)
5.48
0.22
4.0%
8.56
0.45
5.2%
6.49
0.40
6.1%
EO%(%)
2.89
0.22
7.6%
2.07
0.17
8.2%
1.50
0.29
19.4%
BASO%(%)
0.53
0.14
26.8%
0.40
0.09
23.6%
0.57
0.15
26.2%
RET%(%)
2.437
0.055
2.3%
1.966
0.053
2.7%
1.086
0.061
5.6%
RET#(109/L )
126.87
2.74
2.2%
98.57
2.67
2.7%
51.94
2.79
5.4%
RET-He(pg)
33.11
0.06
0.2%
32.60
0.09
0.3%
33.96
0.19
0.6%
*1 WBC-C: The total white blood cell count measured from the forward scattered light and side scattered light of WDF channel (CBC mode).*2 WBC-D: The white blood cell count measured from the WDF channel (CBC + DIFF mode).
Table 8 Within-run reproducibility of the body fluid mode
AVE.
SD
CV
MAX
MIN
AVE.
SD
CV
MAX
MIN
AVE.
SD
CV
MAX
MIN
1
2
3
WBC-BF(109/L )
0.0104
0.0008
8.1%
0.012
0.009
0.0211
0.00209.3%
0.025
0.018
0.0464
0.00265.6%
0.050
0.043
RBC-BF(1012/L )
0.0066
0.000710.6%
0.0080.0060.0118
0.0006
5.4%
0.013
0.0110.0268
0.0006
2.4%
0.028
0.026
TC-BF(109/L )
0.0104
0.0008
8.1%
0.012
0.009
0.0211
0.00209.3%
0.025
0.018
0.0464
0.00265.6%
0.050
0.043
Sysmex Journal International Vol. 25 No. 1 (2015)
− 7 −
Fig. 2-1 Correlations among CBC 8 parameters
y = 1.0094x -0.1048r = 0.9974n = 106
WBC (109/L )
0
5
10
15
20
25
0
XN-5
50
XN-1000
01 51 02 525
y = 0.9987 x+ 0.03r = 0.9984n = 106
RBC (1012/L )
0.0
2.0
4.0
6.0
8.0
0.0XN
-550
XN-1000
8.06.04.02.0
y = 0.9878 x+ 0.7966r = 0.9987n = 106
HGB (g/L )
0
50
100
150
200
0
XN-5
50
XN-1000
20015010050
y = 0.9793x + 0.0076r = 0.9976n = 106
HCT (L/L )
0.0
0.2
0.4
0.6
0.0
XN-5
50XN
-550
XN-1000
0.60.40.2
y = 1.0375x -3.9786r = 0.9946n = 106
MCV (fL)
60
80
100
120
140
XN-5
50
XN-1000
14012010006 08
y = 0.9695 x+ 0.0565r = 0.9900n = 106
MCH (pg)
15
25
35
45
15
XN-5
50
XN-1000
453525
y = 0.9627 x+ 0.0286r = 0.9982n = 106
PLT (10 9/L)
0
200
400
600
800
1,000
XN-5
50
XN-1000XN-1000
1,000002 004 006 0080
Sysmex Journal International Vol. 25 No. 1 (2015)
− 8 −
Fig. 2-2 Correlations among analytical parameters
y = 0.9529 x+ 1.0553r = 0.9910n = 106
RDW-SD (fL)
30
40
50
60
70
80
XN-5
50
XN-100003 04 05 06 07 08
y = 0.9673 x+ 0.3215r = 0.9976n = 106
RDW-CV (%)
10
15
20
25
30
XN-5
50
XN-100001 51 02 52 03
y = 0.8543 x+ 1.4693r = 0.9428n = 105
PDW (fL)
5
10
15
20
XN-5
50
XN-10002015105
y = 0.9526 x+ 0.3205r = 0.9577n = 105
MPV (fL)
6
8
10
12
14
16
XN-5
50
XN-100001 21 41 6186
y = 0.9265 x+ 0.4405r = 0.9766n = 105
P-LCR (%)
0
20
40
60
XN-5
50
XN-10006040200
y = 0.9613x -0.0032r = 0.9949n = 105
PCT (% )
0.0
0.2
0.4
0.6
0.8
1.0
XN-5
50
XN-10000.0 2.0 4.0 6.0 8.0 0.1
y = 0.9764x + 1.2967r = 0.9959n = 106
NEUT% (%)
0
20
40
60
80
100
120
XN-5
50
XN-100002 04 06 08 001 0210
y = 0.984 x+ 0.5881r = 0.9952n = 106
LYMPH% (%)
0
20
40
60
80
0
XN-5
50
XN-100002 04 06 08
y = 0.9651x + 0.2871r = 0.9774n = 106
MONO% (%)
XN-5
50
0
10
20
30
40
0XN-1000
01 02 03 04
y = 0.9604 x+ 0.0875r = 0.9933n = 106
EO% (%)
0
5
10
15
20
25
30
0
XN-5
50
XN-100001 51 02 52 035
y = 0.6356 x+ 0.2632r = 0.6717n = 106
BASO% (%)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0.0
XN-5
50
XN-10005.0 0.1 5.1 0.2 5.2 0.3
y = 0.852 x-0.1624r = 0.9851n = 106
IG% (%)
0
5
10
15
0
XN-5
50
XN-100015105
Fig. 2-3 Correlations among WDF channel parameters
Sysmex Journal International Vol. 25 No. 1 (2015)
− 9 −
Fig. 2-4 Correlations among RET channel parameters
y = 1.0754 x+ 0.6081r = 0.9768n = 106
IRF (%)
0
10
20
30
40
50
60
0
XN-5
50
XN-1000
01 02 03 04 05 06
y = 1.1474 x+ 0.1421r = 0.9833n = 106
HFR (%)
0
10
20
30
0
XN-5
50
XN-1000
302010
y = 0.9835 x+ 1.1739r = 0.9354n = 106
MFR (%)
0
5
10
15
20
25
30
0
XN-5
50
XN-1000
01 51 02 52 035
y = 1.0754x -8.1507r = 0.9768n = 106
LFR (%)
40
60
80
100
120
40
XN-5
50
XN-1000
12010006 08
y = 1.0005 x+ 0.0092r = 0.9963n = 106
RBC-O (1012/L)
0
2
4
6
8
0 2 4 6 8
XN-5
50
XN-1000
y = 1.0455x + 2.7218r = 0.9972n = 106
PLT-O (10 9/L)
0
200
400
600
800
1,000
1,200
0
XN-5
50
XN-1000
1,2001,000800600400200
y = 1.2209 x+ 0.7131r = 0.7779n = 106
IPF (%)
0
5
10
15
20
0
XN-5
50
XN-1000
01 51 025
y = 0.9794x + 0.3284r = 0.9908n = 106
RET-He (pg)
10
20
30
40
50
XN-5
50
XN-1000
01 02 03 04 05
y = 1.0176x -0.6837r = 0.9885n = 106
RET# (10 9/L)
0
50
100
150
200
250
0
XN-5
50
XN-1000
05 001 051 002 052
y = 1.037x -0.5976r = 0.9961n = 106
RET% (%)
0
3
6
9
12
15
0
XN-5
50
XN-1000
1512963
Sysmex Journal International Vol. 25 No. 1 (2015)
− 10 −
Fig. 3 Correlations among body fluid parameters
y = 1.0779x -0.0028r = 0.9977n = 55
PMN# (109/L )
0
2
4
6
8
10
0
X
N-5
50
XN-1000
108642
y = 1.0635x -0.0001r = 0.9997n = 55
MN# (109/L )
0
2
4
6
8
10
0
X
N-5
50
XN-1000
108642
y = 0.9591x+0.00004r = 0.9995n = 55
RBC-BF (1012/L )
0.00
0.02
0.04
0.06
0.08
0.10
0.00
X
N-5
50
XN-1000
0.100.080.060.040.02
y = 1.0722x -0.0059r = 0.9994n = 55
WBC-BF (109/L )
0
2
4
6
8
10
0
X
N-550
XN-1000
108642
y = 0.7236 x+ 21.398r = 0.7825n = 44
MN% (%)*
0
20
40
60
80
100
0
X
N-5
50
XN-1000
10080604020
y = 0.9088x + 2.6322r = 0.9000n = 44
PMN% (%)*
0
20
40
60
80
100
0
X
N-5
50
XN-1000
10080604020
y = 1.067x -0.0081r = 0.9993n = 55
TC-BF# (109/L )
0
2
4
6
8
10
0
X
N-5
50
XN-1000
108642
* MN% and PMN% parameters: N= 44, as samples not satisfying the LoQ (WBC-BF < 0.003 × 109/L) were excluded.
FEATURES
In spite of its small size, XN-L series can provide varioushealthcare information (RET, RET-He, and body fluidparameters) which may assist clinicians in diagnosticdecisions.RET-He reflects the hemoglobin levels in reticulocytesand is a sensitive indicator of iron utilization inerythropoiesis. Thus, it should facilitate the treatment andmanagement of anemia in patients with chronic kidneydisease 7) and improve the safety of autologous blooddonation 8).The XN-L series allows the measurements of white bloodcells, red blood cells, mononuclear cells, andpolymorphonuclear leukocytes in the body fluid mode.Thus, it allows users to make rapid and objective reportsof measurements from emergency tests at non-businesshours, as well as from daily practices. This feature shouldbe particularly useful in the diagnosis of central nervoussystem infection. In addition, it may be utilized as
screening information for cytology to detect tumor cells9).The XN-L series is also equipped with a PLT-I/PLT-Oswitching function. The impedance platelet count (PLT-I)comes from the hydro dynamic focusing method, whilethe optical platelet count (PLT-O) is measured in theRET channel using flow cytometry. Usually, the PLT-I isemployed as platelet count, while the PLT-O isautomatically reported as platelet count for samples withabnormal platelet particle size distributions, such as thosewith fragmented red blood cells 10).This function facilitates reporting of more reliableplatelet counts.In addition, with customers' analytical devices and ourcustomer support centers connected on-line, the XN-Lseries provides real-time quality control and faultmonitoring/repair support on the outsourcing basis, andSNCS® service function providing information on theweb 4, 11). More than 24,000 devices are connected on theweb around the world, facilitating reporting of accuratemeasurements and maintenance of devices.
Sysmex Journal International Vol. 25 No. 1 (2015)
− 11 −
Table 9 Minimum detection sensitivity of the whole blood mode
Table 10 Minimum detection sensitivity of the low WBC mode
Table 11 Minimum detection sensitivity of the body fluid mode
LoB
LoD
LoQ
WBC-C(109/L )
0.01
0.02
0.03
WBC-D(109/L )
0.00
0.01
0.02
RBC(1012/L )
0.00
0.00
0.00
HGB(g/L )
0
0
0
HCT(L/L )
0.000
0.000
0.000
PLT-I(109/L )
0
1
2
PLT-O(109/L )
0
1
2
LoB
LoD
LoQ
WBC-C(109/L )
0.00
0.01
0.01
RBC(1012/L )
0.00
0.00
0.00
HGB(g/L )
0
0
0
HCT(L/L )
0.000
0.000
0.000
PLT-I(109/L )
0
1
2
PLT-O(109/L )
0
1
2
LoB
LoD
LoQ
WBC-BF(109/L )
0.000
0.001
0.002
RBC-BF(1012/L )
0.000
0.000
0.001
TC-BF#(109/L )
0.000
0.001
0.002
ADDITIONAL VALUES
Like XN-Series, the XN-L series also providesparameters such as immature granulocyte (IG) count andIPF.Studies have shown that IG may facilitate the detectionof inflammatory reaction easier and quicker whencombined with existing parameters, such as C-reactiveprotein and erythrocyte sedimentation rate 12).Reticulated platelet counts reflect the platelet productionability of the bone marrow. The XN-L series allowsautomatic measurement of its related parameter IPF. IPFhas been reported useful in predicting platelet recoverytime after chemotherapy or hematopoietic stem celltransplantation 13) and may aid clinicians in thedifferential diagnosis of thrombocytopenic disorders,such as immunological thrombocytopenia (e.g.,idiopathic thrombocytopenic purpura) 14).
CONCLUSIONS
This report introduced the newly released AutomatedHematology Analyzer XN-L series. Using many of thesame technologies as the higher throughput XN-series,these compact analyzers contribute to accuratemeasurement techniques and testing efficiency and canbe customized to fit the unique needs of each customer.In addition, it employs systems developable onward sothat the wide spread usage of hematology analyzers inclinical practice can be expected in future.
References1) Fleming C et al. Validation of the body fluid module on the new
Sysmex XN-1000 for counting blood cells in cerebrospinal fluidand other body fluids. Clin Chem Lab Med. 2012;50(10):1791-8.
2) Briggs C et al. Performance evaluation of the Sysmex haematologyXN modular system. J Clin Pathol. 2012 Nov;65(11): 1024-30.
3) Seo JY et al. Performance evaluation of the new hematologyanalyzer Sysmex XN-series. Int J Lab Hematol. 2015; 37(2): 155-64.
4) Ochi Y et al. Overview of the Automated Hematology AnalyzerXN-Series. Sysmex Journal 2011; 34(2): 1-16. (Japanese).
5) Fujimoto K. Principles of measurement in hematology analyzersmanufactured by Sysmex Corporation. Sysmex JournalInternational. 1999; 9(1): 31-44.
6) Oshiro I et al. New method for hemoglobin determination by usingsodium lauryl sulfate (SLS). Clinical biochemistry. 1982; 15(2):83-88.
7) Miwa N et al. Usefulness of measuring reticulocyte hemoglobinequivalent in the management of haemodialysis patients with irondeficiency. Int J Lab Hematol. 2010; 32(2):248-55.
8) Shibayama M et al. Usefulness of reticulocyte hemoglobinequivalent for the safety of pre-operative autologous blooddonation. Rinsho Byori. 2011; 59(6): 565-70. (Japanese).
9) Zimmermann M et al. Cellular origin and diagnostic significanceof high-fluorescent cells in cerebrospinal fluid detected by the XE-5000 hematology analyzer. International Journal of LaboratoryHematology. 2013; 35(6): 580-588.
10) Inoue H. Overview of Automated Hematology Analyzer XE-2100.Sysmex Journal International. 1999; 9(1): 58-64.
11) Hayashi M. How the IT Revolution is affecting trends in ClinicalTesting. Sysmex Journal International. 2000; 10(1): 1-2.
12) Briggs C et al. Evaluation of immature granulocyte counts by theXE-IG master: upgraded software for the XE-2100 automatedhematology analyzer. Lab. Hematol. 2003; 9(3): 117-24.
13) Yamaoka G et al. The immature platelet fraction is a useful markerfor predicting the timing of platelet recovery in patients withcancer after chemotherapy and hematopoietic stem celltransplantation. Int J Lab Hematol. 2010; 32(6 Pt 1): 208-16.
14) Sakuragi M et al. Clinical significance of IPF% or RP%measurement in distinguishing primary immune thrombocytopeniafrom aplastic thrombocytopenic disorders. Int J Lab Hematol.2015; 101(4): 369-75.
Sysmex Journal International Vol. 25 No. 1 (2015)
− 12 −